EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Intra-articular injection of an extended-release flavopiridol formulation represents a potential alternative to other intra-articular medications for treating equine joint disease

Scott A Katzman, Derek Cissell, Dustin Leale, Marcos Perez-Nogues, Mark D Hall, Grace Bloom, Briana Hamamoto-Hardman, Chun-Yi Wu, Anne K Haudenschild, Gang-Yu Liu, Jasper H N Yik, Dominik R Haudenschild iD

American Journal of Veterinary Research · 2024

DOI: 10.2460/ajvr.24.03.0057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2024. Verfasst von Scott A Katzman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, Davis, CA. Hauptthemen laut MEDLINE: Flavonoids, Horse Diseases, Delayed-Action Preparations, Piperidines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To establish the pharmacokinetics of the cyclin-dependent kinase-9 inhibitor flavopiridol in equine middle carpal joints, using an extended-release poly lactic- co -glycolic acid (PLGA) microparticle formulation. ANIMALS 4 healthy horses without evidence of forelimb lameness. METHODS A 6-week longitudinal pharmacokinetic study was conducted in 2 phases (6 weeks each) in 4 healthy horses. The PLGA microparticles containing 122 μg flavopiridol in 3 mL saline were administered by intra-articular injection into 1 middle carpal joint, with empty PLGA microparticles injected into the contralateral joint as a control. Synovial fluid and plasma were collected at time points out to 6 weeks, and drug concentrations in synovial fluid and plasma were determined using validated protocols. Synovial fluid total protein and total nucleated cell count and differential, CBC, serum biochemistry, and lameness exams were performed at each of the time points. RESULTS Synovial fluid flavopiridol averaged 19 nM at week 1, gradually reduced to 1.4 nM by 4 weeks, and was generally below the detection limit at 5 and 6 weeks. There was no detectable flavopiridol in the plasma samples, and no adverse effects were observed at any time point. CLINICAL RELEVANCE Intra-articular injection of PLGA microparticle-encapsulated flavopiridol was well tolerated in horses, with detectable levels of flavopiridol in the synovial fluid out to 4 weeks with negligible systemic exposure. Flavopiridol is a cyclin-dependent kinase-9 inhibitor with potent anti-inflammatory and analgesic activity. The extended-release microparticle formulation promotes intra-articular retention of the drug and it may be an alternative to other intra-articular medications for treatment of equine joint disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlavonoidsHorse DiseasesDelayed-Action PreparationsPiperidinesSynovial FluidAnimalsHorsesInjections, Intra-ArticularJoint DiseasesMaleFemalePolylactic Acid-Polyglycolic Acid CopolymerLongitudinal Studies

Stichwörter der Autor:innen

equineflavopiridolintra-articularosteoarthritispharmacokinetics

Substanzen

alvocidibFlavonoidsDelayed-Action PreparationsPiperidinesPolylactic Acid-Polyglycolic Acid Copolymer

Autor:innen und Institutionen

  • Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, Davis, CA.
  • Department of Orthopedic Surgery, School of Medicine, University of California-Davis, Davis, CA.
  • William R. Pritchard Veterinary Medical Teaching Hospital, University of California-Davis, Davis, CA.
  • Bioanalysis and Pharmacokinetics Core Facility, University of California-Davis, Davis, CA.
  • Department of Chemistry, University of California-Davis, Davis, CA.
  • Houston Methodist Research Institute, Orthopedics and Sports Medicine, Houston, TX.

ORCID-Profile: Dominik R Haudenschild

Zitieren

APA

Katzman, S. A., Cissell, D., Leale, D., Perez-Nogues, M., Hall, M. D., Bloom, G., Hamamoto-Hardman, B., Wu, C. Y., Haudenschild, A. K., Liu, G. Y., Yik, J. H. N., & Haudenschild, D. R. (2024). Intra-articular injection of an extended-release flavopiridol formulation represents a potential alternative to other intra-articular medications for treating equine joint disease. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.24.03.0057

Vancouver

Katzman SA, Cissell D, Leale D, Perez-Nogues M, Hall MD, Bloom G, et al. Intra-articular injection of an extended-release flavopiridol formulation represents a potential alternative to other intra-articular medications for treating equine joint disease. American Journal of Veterinary Research. 2024. doi:10.2460/ajvr.24.03.0057

BibTeX
@article{Katzman2024,
  author = {Katzman, Scott A and Cissell, Derek and Leale, Dustin and Perez-Nogues, Marcos and Hall, Mark D and Bloom, Grace and Hamamoto-Hardman, Briana and Wu, Chun-Yi and Haudenschild, Anne K and Liu, Gang-Yu and Yik, Jasper H N and Haudenschild, Dominik R},
  title = {Intra-articular injection of an extended-release flavopiridol formulation represents a potential alternative to other intra-articular medications for treating equine joint disease},
  journal = {American Journal of Veterinary Research},
  year = {2024},
  doi = {10.2460/ajvr.24.03.0057}
}
Kostenlos starten →